Increased endothelin-1 (ET-1) or aldosterone may be associated with promotion of cardiovascular hypertrophy and fibrosis. We evaluated whether the selective ET A receptor-antagonist BMS 182874 (BMS) prevents cardiac and vascular collagen deposition and hypertrophy in aldosterone-infused rats. Rats received subcutaneous aldosterone (0.75 g/h) and 1% sodium chloride in drinking water Ϯ BMS (40 mg/kg per day in food) for 6 weeks. Heart and aorta were cross-sectioned and stained with Sirius red. Heart weight did not change with either aldosterone infusion or BMS treatment. Cardiac and aortic interstitial and perivascular collagen were quantified with videomorphometry. Aortic collagen and media cross-sectional area were significantly increased 3.5-fold (P Ͻ .01) and 1.13-fold (P Ͻ .05), respectively, with aldosterone infusion and decreased in BMS-treated rats (P Ͻ .05, P Ͻ .001, respectively). Aldosterone infusion increased interstitial and perivascular collagen in the left (1.6-and 2.7-fold, P Ͻ .05 and P Ͻ .01, respectively) and right ventricle (1.5-and 1.7-fold, P Ͼ .05 and P Ͻ .05, respectively). BMS prevented collagen deposition except for interstitial collagen in the right ventricle. Cardiac and aortic fibrosis were significantly increased in aldosterone-infused hypertensive rats. The ET A receptor antagonist prevented cardiac and aortic collagen deposition and aortic hypertrophy. This suggests a role for ET-1 in fibrosis of heart and large vessels in conditions associated with mineralocorticoid excess. Am J Hypertens 2002;15:164 -169
C
ardiovascular alterations associated with hypertension are characterized by cardiovascular hypertrophy or remodeling associated with an increase in deposition of extracellular matrix (ECM) proteins such as collagen. 1, 2 The mechanism underlying these changes is unclear, but humoral factors, such as angiotensin II (Ang II), 3, 4 endothelin-1 (ET-1), 5 or aldosterone 3, 6, 7 may play a role. The accumulation of ECM in the cardiovascular system is involved in increases in wall stiffness and eventually in the development of heart failure. 8 Indeed, increased stiffness of aorta is an independent predictor of cardiovascular mortality. The enhancement of collagen deposition in the myocardium and around coronary arteries has been demonstrated in other experimental models, including renovascular hypertension, 9, 10 after Ang II or aldosterone infusion, 2, 6, 7, 9 in spontaneously hypertensive rats (SHR), 11 and recently in deoxycorticosterone (DOCA)-salt hypertensive rats. 12, 13 ET-1 plays a role in some models of salt-sensitive experimental hypertension, such as DOCA-or aldosterone-salt hypertensive rats. ET-1, whose expression in blood vessels is increased in these models, 14 -17 and blood pressure (BP) elevation, together participate in the hypertrophy of large and small arteries salt-sensitive hypertension. Administration of endothelin antagonists prevented the development of hypertension and reversed vascular hypertrophy in both large and small arteries, 17 in part by blocking ET-1 hypertrophic and mitogenic properties. 18, 19 ET-1 also promotes growth of cardiomyocytes 20 and collagen synthesis by cardiac fibroblasts. 6 In addition, ET-1 is overexpressed in the heart in endothelin-dependent hypertension. 21 This in turn increases procollagen I and III synthesis leading to abundant cardiac interstitial and perivascular fibrosis, as a result of an imbalance between the synthesis and degradation of collagen. Increased fibrosis will contribute to myocardial stiffness and contractile dysfunction, resulting in cardiac failure.
In the present study, we tested the hypothesis that ET-1 plays a role in cardiac and aortic collagen deposition and hypertrophy in aldosterone-salt hypertensive rats, similar to that which we previously showed in DOCA-salt hypertensive rats, 12 with the activation of ET A receptors.
Methods

Animal Experiments
The 
Collagen Quantification in the Heart
The thoracic aorta and heart fixed in Bouin solution were processed for paraffin embedding in an automated system (SHANDON Citadel tissue processor, Pittsburgh, PA). 
Hypertrophy and Collagen Quantification in the Aorta
The media cross-sectional area in Sirius red-stained aorta was analyzed by the image analysis system (magnification, ϫ10). Collagen content in intima and media of aorta were evaluated and averaged (magnification, ϫ40).
Statistical Analysis
Data are expressed as mean Ϯ SEM. Statistical significance was assessed by one-way ANOVA followed by a Student Newman-Keuls test. Differences were considered significant at P Ͻ .05.
Results
BP, Body, and Heart Weights
As already reported, 17 aldosterone-infusion significantly increased systolic BP to 151 Ϯ 7 mm Hg compared to 108 Ϯ 4 mm Hg of controls (P Ͻ .01) after 6 weeks. Treatment with the selective ET A receptor-antagonist BMS 182874 (BMS) resulted in prevention of BP elevation (117 Ϯ 4 mm Hg). Body weight and relative heart weights were similar in treated and untreated aldosterone-infused hypertensive rats (Table 1) . In the intima-media of aorta, collagen density was markedly increased to 15.2% Ϯ 2.4% by aldosterone infusion (versus control of 4.3% Ϯ 0.5%, P Ͻ .01). BMS decreased collagen deposition to 9.2% Ϯ 1.2% (P Ͻ .05).
Effects of ET A Receptor Antagonist BMS 182874 on Cardiac Fibrosis
Myocardial fibrosis was enhanced by aldosterone infusion in the interstitial and perivascular regions of the left ventricle (1.6-and 2.7-fold, P Ͻ .05 and P Ͻ .01, respectively) and perivascularly in the right ventricle (1.7-fold, P Ͻ .05), compared to normotensive control rats (Figs. 3  and 4) . Interstitial collagen density in the right ventricle did not increase significantly in aldosterone-infused rats (1.5-fold, P Ն .05). BMS prevented cardiac collagen deposition except for interstitial collagen of the right ventricle (Fig. 4) . Increase in interstitial collagen was very important in the subendocardial myocardium compared to the subepicardial or mid-myocardial regions of the left ventricle of aldosterone-salt rats (Fig. 5) . Treatment with BMS prevented collagen deposition to the greatest degree in the subendocardial myocardium of the left ventricle after aldosterone infusion.
Discussion
We previously found that aldosterone infusion into normotensive rats increased tissue preproET-1 mRNA levels in large and small arteries, which in turn played a major role in ET-1-stimulated vascular hypertrophy and hypertension in vivo. 17 Similarly, increased expression of cardiac ET-1 was demonstrated in DOCA-salt hypertensive rats, [12] [13] [14] [15] 21 and it was also shown that ET-1 may be involved in cardiac hypertrophy in some experimental rat models. 22, 23 This study further demonstrates that aldosterone infusion significantly increases collagen deposition in the heart and aorta. Treatment with the ET A -selective endothelin receptor antagonist BMS 182874 prevented collagen deposition in the heart and aorta.
The presence of aldosterone receptors on large arteries such as aorta and in the heart, 24, 25 and the recent discovery of vascular 26 and cardiac 27 synthesis of aldosterone suggest that this hormone plays a significant role in the regulation of the cardiovascular structure. The role of endogenous aldosterone in large artery fibrosis and hypertrophy in hypertension is presently uncertain. The mineralocorticoid receptor antagonist spironolactone has antifibrotic properties. An effect of aldosterone on adventitial fibroblasts is a potential explanation for increased collagen synthesis induced by aldosterone, as demonstrated on cardiac fibroblasts. 28, 29 Aldosterone increases vascular and cardiac preproET-1 mRNA levels, which mediates partly by transforming growth factor-␤ 1 ET-1-stimulated cardiac fibrosis in DOCA-salt hypertensive rats, 12 and vascular growth in this model and the aldosterone salt-loaded rat. 16, 17 Blockade of ET A receptors prevented the development of hypertension, vascular hypertrophy, and cardiac fibrosis in both experimental models. Mineralocorticoids may also potentiate the action of vasopressin on ET-1 expression in blood vessels and heart, or alternatively, mineralocorticoids may stimulate directly or indirectly vasopressin, which in turn may stimulate ET-1 expression. 30, 31 Although the development of cardiac fibrosis and left ventricular hypertrophy concomitant with BP increase in the aldosterone-salt model may indicate a role for BP elevation, cardiac fibrosis occurs in both ventricles, whereas atrial natriuretic peptide gene expression is stimulated only in the left but not the right ventricle. Furthermore, prevention of cardiac fibrosis by subhypotensive doses of spironolactone 7, 32 supports a BP independent effect of aldosterone in the induction of cardiac fibrosis. In the present study BP increase was prevented by the ET A antagonist. This raises the question whether the fact that BP did not increase prevented cardiac fibrosis in aldosterone-infused ET A antagonist-treated rats. In this model cardiac fibrosis affects both the right and the left ventricle, which is more typically a hormonal than a hemodynamic effect, as discussed above. This has allowed investigators in this field to attribute cardiac fibrosis in aldosteroneinfused rats to direct aldosterone effects rather than to BP elevation. 7, 9, [32] [33] [34] [35] By the same token, correction of fibrosis with ET A antagonism in both right and left ventricles may be attributed with the same confidence to blockade of the action of ET-1 rather than to BP control. In this particular study and in contrast to experiments of other investigators, 6, 7, 9, 33 aldosterone plus salt treatment was not associated with cardiac hypertrophy. Rats did not undergo unilateral nephrectomy in the present study, which may result in lesser BP elevation than previous studies. Thus, differences in protocol and its duration (6 weeks in this study v 8 weeks in studies from other investigators), may explain the absence of cardiac hypertrophy in the present work.
Aldosterone infusion caused little evidence of cardiac hypertrophy, but slight and significant elevation in BP and marked accumulation of collagen. Collagen deposition was increased to the same extent in the right and left ventricles as previously reported in other studies. This suggests that in aldosterone-infused rats, extracellular matrix deposition is more dependent on neurohormonal influences such as the activation of sympathetic nerves or the endothelin system than on pressure overload or the degree of left ventricular hypertrophy. Blood pressure elevation may have less influence on cardiac collagen deposition than on development of cardiac hypertrophy, in contrast to aldosterone, 33 similar to what occurs in DOCA hypertensive rats. 12, 13, [15] [16] [17] Because in the heart, ET-1 overexpression appeared to occur mainly in endothelium of blood vessels, 15 ET-1 produced in blood vessels of the heart may influence interstitial fibroblasts and stimulate collagen production, but could conceivably have only a minor effect on cardiomyocytes.
Perivascular cardiac fibrosis generally appears first, followed later by interstitial fibrosis in experimental hypertension associated with unilateral renal ischemia. 34 This is similar to the present findings that showed more accumulation of perivascular collagen than interstitial collagen in the aldosterone-infused rat. However, Brilla et al 3 showed that aldosterone infusion in uninephrectomized rats drinking 1% NaCl induced marked accumulation of interstitial collagen in both ventricles, and to a lesser extent, or not at all, an increase in perivascular collagen. Interestingly, DOCA has been shown to increase mainly perivascular fibrosis, whereas aldosterone, for a similar BP increase, increased both interstitial and perivascular fibrosis. 35 The ET A antagonist treatment of aldosterone-infused hypertensive rats completely prevented development of hypertension and interstitial fibrosis of the left ventricle and perivascular collagen in both ventricles and in aorta, but interstitial fibrosis of the right ventricle was unaffected. Prevention of fibrosis in the myocardium may occur with a different time course in different animal models and in both ventricles, suggesting that different mechanisms may be involved.
Cardiac fibrosis occurred in aldosterone-infused hypertensive rats predominantly in the subendocardial and to a lesser extent in the mid-myocardial or subepicardial myocardium of the left ventricle, as previously found in DOCA-salt hypertensive rats. 12 In DOCA-salt hypertensive rats increased density of small arterioles, 20 m in lumen diameter, and capillary rarefaction occurred mainly in the subendocardial myocardium, which was in part corrected by treatment with an ET A antagonist. 36 Vascular overproduction of ET-1 may be a mechanism shared by cardiac fibrosis and vascular changes in endothelin-dependent hypertension in rats. Increased arteriolar density may increase coronary vascular resistance as arteriolar segments become longer. Decreased capillary density and fibrosis may compromise oxygen and nutrient supply to cardiac myocytes, contributing to hypoxia in this area of the myocardium, which is most vulnerable. Whereas hemodynamic and metabolic variables probably participate together with ET-1 and other hormonal stimuli to induce vascular growth and rarefaction in the subendocardial region in the heart of aldosterone-salt hypertensive rats, ET-1 may play a critical role in fibrosis as demonstrated by its abrogation by ET A antagonism.
It should be noted that aldosterone-infused rats received salt. In most studies in which an endothelindependent component has been demonstrated participating in vascular or cardiac changes, salt has been administered. [12] [13] [14] [15] [16] [17] 22, 37 In most studies in which effects of aldosterone have been studied on cardiac fibrosis, salt has also been administered to rats. 6, 7, 9, [33] [34] [35] Thus, salt is playing a role in this paradigm. However, the relative importance of the roles of aldosterone and salt remain to be clarified.
In conclusion, significantly increased collagen deposition was observed in the aorta and the heart of aldosteroneinfused hypertensive rats, a change abrogated by treatment with an ET A receptor antagonist. Although a role of the prevention of BP increase cannot be ruled out, the fact that fibrosis occurred in the right and left ventricle, and both were abrogated in ET A antagonist-treated rats supports the hypothesis that in this model fibrosis is aldosterone and ET-1 dependent rather than BP dependent. If ET-1 plays a critical role in cardiac fibrosis in aldosterone-infused hypertensive rats, as suggested in this study, it may have pathophysiologic implications in hypertension by contributing to myocardial stiffness and contractile dysfunction. Blockade of ET A receptors may have beneficial effects on the heart and large arteries in those forms of hypertension in which the endothelin system is activated, through blunting of cardiovascular fibrosis and remodeling.
